Literature DB >> 1035802

Effects of imipramine, chlorimipramine, and fluoxetine on cataplexy in dogs.

D A Babcock, E L Narver, W C Dement, M M Mitler.   

Abstract

Four narcoleptic dogs with cataplexy were given trials with the serotonin uptake blockers imipramine and chlorimipramine (known to be effective in treating cataplexy in humans). An even more selective serotonin uptake blocker, fluoxetine, was also tested. Injections of placebo, test compound, and placebo were given respectively on 3 successive days. Anticataplectic effects were measured approximately 30 min, 3 hr, and 6 hr postinjection by recording elapsed time and number of cataplectic episodes during the dogs' attempts to eat ten pieces of a desired food presented in a standard fashion. Imipramine (1 mg/kg) and fluoxetine (1.5 and 3.0 mg/kg)significantly improved performance, while chlorimipramine (0.5-5 mg/kg) had no clear effect. Data were not totally consistent with the notion that serotonin uptake blockers improve cataplexy in dogs, since chlorimipramine was not effective in these animals.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1035802     DOI: 10.1016/0091-3057(76)90298-7

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  9 in total

Review 1.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

2.  Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function.

Authors:  Sawako Tabuchi; Tomomi Tsunematsu; Sarah W Black; Makoto Tominaga; Megumi Maruyama; Kazuyo Takagi; Yasuhiko Minokoshi; Takeshi Sakurai; Thomas S Kilduff; Akihiro Yamanaka
Journal:  J Neurosci       Date:  2014-05-07       Impact factor: 6.167

3.  Prostaglandin E2 and its methyl ester reduce cataplexy in canine narcolepsy.

Authors:  S Nishino; E Mignot; B Fruhstorfer; W C Dement; O Hayaishi
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

4.  Role of the medial prefrontal cortex in cataplexy.

Authors:  Yo Oishi; Rhiannan H Williams; Lindsay Agostinelli; Elda Arrigoni; Patrick M Fuller; Takatoshi Mochizuki; Clifford B Saper; Thomas E Scammell
Journal:  J Neurosci       Date:  2013-06-05       Impact factor: 6.167

5.  Animal models of narcolepsy.

Authors:  Lichao Chen; Ritchie E Brown; James T McKenna; Robert W McCarley
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-08       Impact factor: 4.388

Review 6.  Narcolepsy: neural mechanisms of sleepiness and cataplexy.

Authors:  Christian R Burgess; Thomas E Scammell
Journal:  J Neurosci       Date:  2012-09-05       Impact factor: 6.167

7.  Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers.

Authors:  E Mignot; A Renaud; S Nishino; J Arrigoni; C Guilleminault; W C Dement
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs.

Authors:  Pamela L Tannenbaum; Joanne Stevens; Jacquelyn Binns; Alan T Savitz; Susan L Garson; Steven V Fox; Paul Coleman; Scott D Kuduk; Anthony L Gotter; Michael Marino; Spencer J Tye; Jason M Uslaner; Christopher J Winrow; John J Renger
Journal:  Front Behav Neurosci       Date:  2014-05-16       Impact factor: 3.558

9.  Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man.

Authors:  Anthony L Gotter; Mark S Forman; Charles M Harrell; Joanne Stevens; Vladimir Svetnik; Ka Lai Yee; Xiaodong Li; Anthony J Roecker; Steven V Fox; Pamela L Tannenbaum; Susan L Garson; Inge De Lepeleire; Nicole Calder; Laura Rosen; Arie Struyk; Paul J Coleman; W Joseph Herring; John J Renger; Christopher J Winrow
Journal:  Sci Rep       Date:  2016-06-03       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.